[AI]+[Progress]: GenoAI Genomic Variant Interpretation System Cuts Whole-Genome Analysis from 72 Hours to 45 Minutes

Article Body

Genomic data analysis has long been a bottleneck for precision medicine. A 30x coverage whole-genome sequencing dataset contains approximately 100GB of raw files, and the traditional analysis pipeline involves four stages: sequence alignment, variant calling, annotation, and clinical interpretation, typically requiring 48 to 72 hours. The GenoAI system released in May 2030 is changing this landscape.

GenoAI was jointly developed by sequencing giant Illumina and the Broad Institute, jointly operated by MIT and Harvard University. The system's core innovation is that it bypasses the traditional sequence alignment step and identifies genetic variants directly from the raw electrical current signals produced by nanopore sequencers.

Mark Daly, head of computational genomics at the Broad Institute, explained: "The traditional process is like first translating a book into another language, then looking for typos in the translated version. GenoAI's approach is to read the original manuscript directly, and only perform localized translation verification when something suspicious is found."

GenoAI employs a deep learning architecture called a "signal graph network." This architecture converts the continuous electrical signals from the sequencer into a temporal graph structure, where each node represents a nucleotide sequence window and edges represent signal correlations between adjacent windows. The graph neural network performs message passing on this structure, simultaneously completing base calling and variant detection.

In terms of performance, GenoAI achieves a detection rate of 99.89% for single nucleotide variants and 99.21% for insertion-deletion variants, both exceeding the best performance of the traditional tool GATK. More critically, analysis time has been reduced from 72 hours to 45 minutes, with 30 minutes for data transfer and only 15 minutes for actual computation.

For clinical applications, GenoAI has been deployed in the neonatal intensive care unit at Boston Children's Hospital. Robert Green, the hospital's genetics director, said: "For newborns with suspected genetic disorders, we used to wait 3 to 5 days for genomic analysis results. Now the entire process, from blood draw to report, can be completed within 2 hours."

However, GenoAI's deployment faces cost challenges. The system requires Illumina's latest NovaSeq X Plus sequencer and dedicated GPU clusters, with hardware depreciation costs of approximately $680 per whole-genome analysis. While lower than the approximately $900 comprehensive cost of traditional workflows, the upfront equipment investment threshold is significant.

Additionally, the system currently only supports human whole-genome analysis, with support for microbiome analysis, tumor somatic mutation detection, and other scenarios still in development. Illumina plans to release a dedicated version for tumor liquid biopsy in Q3 2030.